RYTM
RYTM clinical trials: RHYTHM PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where RHYTHM PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 33
- Trials linked
- 29
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RYTM on the catalyst calendar · RYTM registry changes
- Primary completion Nov 3, 2026ActualPhase 2NCT06772597A Study of Setmelanotide in Patients With Prader-Willi SyndromeRhythm Pharmaceuticals, Inc. · Prader-Willi SyndromeActive, not recruitingRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2026ActualPhase 2NCT06046443A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityRhythm Pharmaceuticals, Inc. · Hypothalamic ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2025ActualPhase 3NCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayRhythm Pharmaceuticals, Inc. · ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2027Sponsor estimatePhase 1/Phase 2NCT06239116A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentRhythm Pharmaceuticals, Inc. · Hypothalamic ObesityActive, not recruitingRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 18, 2025ActualPhase 3NCT05774756A Trial of Setmelanotide in Acquired Hypothalamic ObesityRhythm Pharmaceuticals, Inc. · Hypothalamic ObesityActive, not recruitingRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2026ActualPhase 3NCT06596135Open-Label Extension Study of SetmelanotideRhythm Pharmaceuticals, Inc. · Obesity Associated With Defects in Leptin-melanocortin PathwayCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 13, 2027Sponsor estimatePhase 3NCT06760546A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)Rhythm Pharmaceuticals, Inc. · Hypothalamic ObesityRecruitingRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 15, 2028Sponsor estimatePhase 2NCT07156578A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)Rhythm Pharmaceuticals, Inc. · Hypothalamic ObesityEnrolling by invitationRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 4, 2023ActualPhase 2NCT04963231DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayRhythm Pharmaceuticals, Inc. · Genetic ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2025ActualPhase 2/Phase 3NCT03651765Long Term Extension Trial of SetmelanotideRhythm Pharmaceuticals, Inc. · Obesity Associated With Defects in Leptin-melanocortin PathwayCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 28, 2022ActualPhase 2NCT04725240Open-Label Study of Setmelanotide in Hypothalamic ObesityRhythm Pharmaceuticals, Inc. · Hypothalamic ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 19, 2023ActualPhase 3NCT05194124Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayRhythm Pharmaceuticals, Inc. · Bardet-Biedl SyndromeCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 18, 2023ActualPhase 3NCT04966741Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityRhythm Pharmaceuticals, Inc. · Bardet-Biedl SyndromeCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2022ActualPhase 4NCT05046132Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy ParticipantsRhythm Pharmaceuticals, Inc. · HealthyCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2020ActualPhase 3NCT03746522Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants...Rhythm Pharmaceuticals, Inc. · Bardet Biedl Syndrome (BBS)CompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 25, 2020ActualPhase 3NCT02896192Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityRhythm Pharmaceuticals, Inc. · Pro-opiomelanocortin (POMC) Deficiency ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2022ActualPhase 2NCT03013543Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityRhythm Pharmaceuticals, Inc. · Genetic ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2013ActualPhase 2NCT01749137Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsRhythm Pharmaceuticals, Inc. · OverweightCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 1/Phase 2NCT02041195Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsRhythm Pharmaceuticals, Inc. · Overweight and ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 26, 2016ActualPhase 2NCT02311673Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeRhythm Pharmaceuticals, Inc. · Prader-Willi SyndromeCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2020ActualPhase 3NCT03287960Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityRhythm Pharmaceuticals, Inc. · Leptin Receptor Deficiency ObesityCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 9, 2020ActualNo phase registeredNCT02849977Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult VolunteersRhythm Pharmaceuticals, Inc. · Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene MutationsCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05183802An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)Rhythm Pharmaceuticals, Inc. · Bardet-Biedl Syndrome (BBS)Approved for marketingRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2018ActualPhase 2NCT03262610Setmelanotide in a Single Patient With Partial LipodystrophyRhythm Pharmaceuticals, Inc. · HypertriglyceridemiaCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 17, 2021ActualPhase 1NCT04348175A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal ImpairmentRhythm Pharmaceuticals, Inc. · Renal InsufficiencyCompletedRYTMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 8 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner